Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Supernus Pharmaceuticals, Inc.
Age
18–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participants must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s) from just prior to receiving study drug through nine days (Day 12) after the end of the infusion
Participants had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
Participant had a HAM-D total score of ≥26 at screening and Day 1 (prior to dosing)
Participant was ≤6 months postpartum at screening
Participant was amenable to IV therapy
You may not be if
Active psychosis
Attempted suicide associated with index case of postpartum depression
Medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder.
Clareo Health | A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
